{
  "id": 14312626,
  "title": "Enhanced CAR T-cell therapy shows early promise for B-cell cancers in first-in-human trial",
  "url": "https://urgent.news/2026/10/13/enhanced-car-t-cell-therapy-shows-early-promise-for-b-cell-cancers-in",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-13T23:00:01.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-10-car-cell-therapy-early-cancers.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "A Phase I clinical trial led by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James) has shown promising results for enhanced CAR T-cell therapy in B-cell blood cancers. The study, published in Blood Cancer Discovery, targeted three proteins—CD19, CD20, and CD22—along with a fourth protein called OX40 to boost the immune response in patients. This approach resulted in remission in mantle cell lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma. CAR T-cell therapy has been effective in treating B-cell blood cancers, but many patients experience relapse within a year, leaving limited treatment options. The trial, involving 18 patients with a median age of 64, demonstrated the feasibility of rapid manufacturing and infusion of fresh cells, resulting in positive outcomes with minimal side effects.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}